Crinetics Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jeff Hung - Morgan Stanley - Analyst : <_ALACRA_META_ABSTRACT>So for those who may not be as familiar with Crinetics, can you provide a brief introduction?

Question: Jeff Hung - Morgan Stanley - Analyst : Great. Well, let's start with Paltusotine. Can you just talk about acromegaly, how patients are currently treated, and the potential benefits of Paltusotine? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 9:35PM, CRNX.OQ - Crinetics Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference

Question: Jeff Hung - Morgan Stanley - Analyst : Now, you reported positive day three results from both your PATHFINDER-1 and 2 study. Can you just remind us what you saw?

Question: Jeff Hung - Morgan Stanley - Analyst : Definitely. So the NDA submission is on track for this year. What remains outstanding to the submission? And I guess besides assembling the application, are there any other gating factors on things that still need to be collected?

Question: Jeff Hung - Morgan Stanley - Analyst : Can you just talk about your launch strategy and what activities are underway and how are you progressing towards those?

Question: Jeff Hung - Morgan Stanley - Analyst : Great. Let's shift to the second indication, carcinoid syndrome. Can you just talk a little bit about carcinoid syndrome? And then earlier this year, you announced the positive Phase 2 results. So can you just remind us what you saw there?

Question: Jeff Hung - Morgan Stanley - Analyst : Now, you'll be starting the Phase 3 this year after meeting with the FDA. Where are you in your conversations with the agency? And has that meeting been scheduled? And what do you think the main aspects that would need to get signed off from the FDA?

Question: Jeff Hung - Morgan Stanley - Analyst : In terms of the study design, how do you think about the potential for measuring breakthrough symptoms that occur with standard of care SRLs?

Question: Jeff Hung - Morgan Stanley - Analyst : And then as you think about commercializing Paltusotine for acromegaly, can you just talk about the potential physician overlap with carcinoid syndrome and what kind of synergy that you would expect with the two potential launches?

Question: Jeff Hung - Morgan Stanley - Analyst : Great. Let's move to your second asset, [atenomen]. Can you just talk about CAH and why atenomen represents the next generation of therapies for CAH?

Question: Jeff Hung - Morgan Stanley - Analyst : Now, you presented initial results recently at endo. Could you just talk about what you saw for the data in CAH and how that's differentiated?

Question: Jeff Hung - Morgan Stanley - Analyst : Okay. And so for that data update, can you just talk a little bit about more of what we should expect to see from that update? How might it be different than what we saw from endo?

Question: Jeff Hung - Morgan Stanley - Analyst : And where do you think atenoma best competes in the CAH market, or how do you see it being positioned in the treatment paradigm?

Question: Jeff Hung - Morgan Stanley - Analyst : And I know it's still a little early, but what is your latest thinking on the potential design of the Phase 3 and potential endpoint that you might use? Should we expect it to be similar to that that was used in Crinecerfont, or are you likely to adjust that endpoint?

Question: Jeff Hung - Morgan Stanley - Analyst : Now, the second indication for altenana is Cushing's disease. Can you just talk a little bit about Cushing's disease? And Endo, you also presented initial data for that indication. Can you just remind us of what you saw?

Question: Jeff Hung - Morgan Stanley - Analyst : Great. Now, you're also expecting to report additional data by year-end. What should we expect to see for Cushing's disease?

Question: Jeff Hung - Morgan Stanley - Analyst : Great. Maybe one last question on the early-stage programs. You're undergoing candidate selection this year for a number of early-stage programs. So which of those programs do you find most interesting?

Question: Jeff Hung - Morgan Stanley - Analyst : Well, looks like we'll end there. Thanks so much for your time.